Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Table 4 Rates of physician’s preference^a (mITT/ITT/PP population)

mITT	Arm A (N = 5)		Arm B (N = 8)		Total (N = 13)
mITT	n (%)	95%-CI	n (%)	95%-CI	n (%)	95%-CI
Cap+Bev	3 (60.0%)	[14.7, 94.7]	3 (37.5%)	[8.5, 75.5]	6 (46.2%)	[19.2, 74.9]
Eve+Exe	2 (40.0%)	[5.3, 85.3]	2 (25.0%)	[3.2, 65.1]	4 (30.8%)	[9.1, 61.4]
I cannot decide	0		3 (37.5%)	[8.5, 75.5]	3 (23.1%)	[5.0, 53.8]
ITT	Arm A (N = 39)		Arm B (N = 38)		Total (N = 77)
ITT	n (%)	95%-CI	n (%)	95%-CI	n (%)	95%-CI
Cap+Bev	10 (25.6%)	[13.0, 42.1]	10 (26.3%)	[13.4, 43.1]	20 (26.0%)	[16.6, 37.2]
Eve+Exe	5 (12.8%)	[4.3, 27.4]	5 (13.2%)	[4.4, 28.1]	10 (13.0%)	[6.4, 22.6]
I cannot decide	2 (5.1%)	[0.6, 17.3]	4 (10.5%)	[2.9, 24.8]	6 (7.8%)	[2.9, 16.2]
PP	Arm A (N = 13)		Arm B (N = 18)		Total (N = 31)
PP	n (%)	95%-CI	n (%)	95%-CI	n (%)	95%-CI
Cap+Bev	8 (61.5%)	[31.6, 86.1]	10 (55.6%)	[30.8, 78.5]	18 (58.1%)	[39.1, 75.5]
Eve+Exe	5 (38.5%)	[13.9, 68.4]	5 (27.8%)	[9.7, 53.5]	10 (32.3%)	[16.7, 51.4]
I cannot decide	0		3 (16.7%)	[3.6, 41.4]	3 (9.7%)	[2.0, 25.8]

^aPhysician’s preference was evaluated after 12 weeks of second-line treatment, assessed by the Physician Preference Questionnaire. Confidence interval was calculated using the Clopper-Pearson formula. Discrepancies between the sum of patients in the ITT population and the total n reported are due to patients, who did not cross over to the second-line therapy. mITT = modified ITT; ITT = intent-to-treat; PP = per-protocol; CI = confidence interval

ISSN: 1471-2407